Navigation Links
Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology
Date:10/6/2009

BETHLEHEM, Pa., Oct. 6 /PRNewswire/ -- Particle Sciences has announced today that they have been engaged by Dow Corning to develop technology for a key Dow Corning product development project. Bruce Frank, Director of Project Management for Particle Sciences remarked, "This is a little outside our normal focus of pharmaceutical development but the technological approach is perfectly analogous. We expect to provide a novel and robust solution that allows Dow Corning to develop a product that will benefit its customers." Andrew Loxley, Director, New Technologies for Particle Sciences added that "Particle Sciences is leveraging its extensive experience and expertise to evaluate a number of technologies deemed suitable for the complex performance characteristics of this particular product. Developing a suitable approach will lead directly to a fast-track scale-up and technology transfer program to commercialize this product." Additional terms of the agreement have not been released.

About Dow Corning

Dow Corning Corporation provides performance-enhancing solutions to serve the diverse needs of more than 25,000 customers worldwide. A global leader in silicones, silicon-based technology and innovation, Dow Corning offers more than 7,000 products and services via the company's Dow Corning(®) and XIAMETER(®) brands. Dow Corning is a joint venture equally owned by The Dow Chemical Company and Corning, Incorporated. More than half of Dow Corning's annual sales are outside the United States.

About Particle Sciences

Particle Sciences is a Bethlehem, PA based Contract Formulation and Analytical Services company that focuses on the Pharmaceutical Industry. Their services include the development of novel encapsulation and drug delivery technologies including drug-device combination products, nanoparticle production and characterization, cGMP analytical services and clinical drug product manufacturing for Phase I and II clinical trials. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

    Maureen Cochran 610-861-4701

SOURCE Particle Sciences


'/>"/>
SOURCE Particle Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
2. Engineers produce how-to guide for controlling the structure of nanoparticles
3. New discovery reveals fate of nanoparticles in human cells
4. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
5. Bio-enabled, surface-mediated approach produces nanoparticle composites
6. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
7. Capping a two-faced particle gives duke engineers complete control
8. Nanotech particles affect brain development in mice
9. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
10. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... a distinguished life sciences expert with a proven track record in strategic global ... range of services related to laboratory testing and analysis for the pharmaceutical, medical ...
(Date:3/27/2017)... Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture ... added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... USA ) and the US National Institutes of Health. ... ... Logo ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led ... grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The ... treating coronary artery disease (CAD). Lam is an assistant professor at the Department ...
(Date:3/24/2017)... and ROCKVILLE, Md. , March 24, ... Maxwell Biotech Venture Fund (MBVF), today announced positive results ... to the standard drug therapy regimen in patients with ... molecule drug discovered by scientists at Sequella, Inc. ( ... of Health. A total of 140 ...
Breaking Biology Technology:
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
Breaking Biology News(10 mins):